It’s time for Congress to end Big Pharma’s war on generics 

Published



Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of patients, and the employers, unions, or programs such as Medicare that provide their drug coverage, the cost of some life-saving brand drugs is staggering.

The brand drug lobby tells us these sky-high prices are a necessity of the remarkable innovation we enjoy in healthcare. And make no mistake, that innovation is important. But as a growing amount of research shows, for many drugs this is an illusion. The high prices are part of Big Pharma’s masterclass in patent loopholes and legal maneuvering. They are waging a war on generic drug competition and artificially keeping prices too high for too long for too many.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.